Telomir Pharmaceuticals, Inc. Common Stock (TELO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.17 (+4.46%), Market cap $0.08B, 52-week low–high $1.08 ~ $2.29.
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headq
Financial statements, price targets, institutional (13F) holdings and related news for Telomir Pharmaceuticals, Inc. Common Stock are updated in real time on BlackAll Trade.
Telomir Pharmaceuticals, Inc. Common Stock trades at $1.17 (+4.46%). Real-time quotes and charts are available on BlackAll Trade.
Telomir Pharmaceuticals, Inc. Common Stock has a market cap of about $0.08B.
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-rel